KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Cash & Equivalents (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Cash & Equivalents for 17 consecutive years, with $10.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 1.32% to $10.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $10.2 billion, a 1.32% decrease, with the full-year FY2025 number at $10.2 billion, down 1.32% from a year prior.
  • Cash & Equivalents was $10.2 billion for Q4 2025 at Bristol Myers Squibb, down from $15.7 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $15.7 billion in Q3 2025 to a low of $6.3 billion in Q2 2024.
  • A 5-year average of $10.5 billion and a median of $10.5 billion in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 44.7% in 2021, then skyrocketed 100.21% in 2025.
  • Bristol Myers Squibb's Cash & Equivalents stood at $14.0 billion in 2021, then tumbled by 34.74% to $9.1 billion in 2022, then grew by 25.66% to $11.5 billion in 2023, then fell by 9.75% to $10.3 billion in 2024, then dropped by 1.32% to $10.2 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Cash & Equivalents are $10.2 billion (Q4 2025), $15.7 billion (Q3 2025), and $12.6 billion (Q2 2025).